Glibenclamide induces collagen iv catabolism in high glucose-stimulated mesangial cells

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Zhu, Liping ^a   Cortes, Pedro ^a   Hassett, Clare ^a   Taube, David W ^a   Yee, Jerry ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GELATINASE A; GLIBENCLAMIDE; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ANTIDIABETIC AGENT; ENZYME INHIBITOR; MESSENGER RNA; MMP2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COLLAGEN METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HYPERGLYCEMIA; METABOLISM; PROTEIN STABILITY; SECOND MESSENGER; WISTAR RAT;

ANIMALS; CELLS, CULTURED; COLLAGEN TYPE IV; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GLYBURIDE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MATRIX METALLOPROTEINASE 2; MESANGIAL CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STABILITY; RATS; RATS, WISTAR; RNA, MESSENGER; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 84867391577     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/183535     Document Type: Article

References (47)

1. Biederman J. I., Vera E., Rankhaniya R., Hassett C., Giannico G., Yee J., Cortes P., Effects of sulfonylureas, α -endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes. Kidney International 2005 67 2 554 565 2-s2.0-12344284788 10.1111/j.1523-1755.2005.67112.x (Pubitemid 40139847)
2. Chiou W. L., Robbie G., Chung S. M., Wu T. C., Ma C., Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharmaceutical Research 1998 15 9 1474 1479 2-s2.0-0031723045 10.1023/A:1011974226596 (Pubitemid 28427939)
3. Qian Y., Feldman E., Pennathur S., Kretzler M., Brosius F. C., From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008 57 6 1439 1445 2-s2.0-48249127629 10.2337/db08-0061
4. Baccora M. H. A., Cortes P., Hassett C., Taube D. W., Yee J., Effects of long-term elevated glucose on collagen formation by mesangial cells. Kidney International 2007 72 10 1216 1225 2-s2.0-35848946413 10.1038/sj.ki.5002517 (Pubitemid 350059662)
5. Chen S., Jim B., Ziyadeh F. N., Diabetic nephropathy and transforming growth factor- β: transforming our view of glomerulosclerosis and fibrosis build-up. Seminars in Nephrology 2003 23 6 532 543 2-s2.0-0348226831 (Pubitemid 38030087)
6. Riser B. L., Cortes P., Yee J., Sharba A. K., Asano K., Rodriguez-Barbero A., Narins R. G., Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF- β Journal of the American Society of Nephrology 1998 9 5 827 836 2-s2.0-0031971189
7. Whiteside C. I., Dlugosz J. A., Mesangial cell protein kinase C isozyme activation in the diabetic milieu. American Journal of Physiology. Renal Physiology 2002 282 6 F975 F980 2-s2.0-0036086641 (Pubitemid 34654462)
8. Nichols C. G., KATP channels as molecular sensors of cellular metabolism. Nature 2006 440 7083 470 476 2-s2.0-33645322386 10.1038/nature04711
9. + channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004 53 supplement 3 S156 S164 2-s2.0-9444284451 10.2337/diabetes.53.suppl3.S156 (Pubitemid 39564538)
10. + channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes/Metabolism Research and Reviews 2006 22 5 341 347 2-s2.0-33749003103 10.1002/dmrr.621 (Pubitemid 44446428)
11. Ashcroft F. M., Gribble F. M., Tissue-specific effects of sulfonylureas. Lessons from studies of cloned K ATP channels. Journal of Diabetes and its Complications 2000 14 4 192 196 2-s2.0-0033816581 10.1016/S1056-8727(00)00081-7
12. Metzger F., Löffler C., Quast U., Sulphonylurea binding in rat isolated glomeruli: pharmacological characterization and dependence on cell metabolism and cytoskeleton. Naunyn-Schmiedeberg's Archives of Pharmacology 1997 355 2 141 149 2-s2.0-0031012405 10.1007/PL00004925 (Pubitemid 27065302)
13. Asano K., Cortes P., Garvin J. L., Riser B. L., Rodríguez-Barbero A., Szamosfalvi B., Jerry Y., Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Kidney International 1999 55 6 2289 2298 2-s2.0-0033064841 10.1046/j.1523-1755.1999.00485.x (Pubitemid 29256483)
14. + channel. Kidney International 2002 61 5 1739 1749 2-s2.0-0036237856 10.1046/j.1523-1755.2002.00302.x (Pubitemid 34437927)
15. Cortes P., Riser B. L., Asano K., Rodríguez-barbero A., Narins R. G., Yee J., Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Kidney International 1998 54 6 1985 1998 2-s2.0-0031783730 10.1046/j.1523-1755.1998.00207.x (Pubitemid 28533626)
16. Giannico G., Cortes P., Baccora M. H., Hassett C., Taube D. W., Yee J., Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells. American Journal of Physiology. Renal Physiology 2007 292 1 F57 F65 2-s2.0-33846244681 10.1152/ajprenal.00210.2006 (Pubitemid 46105243)
17. Glass D. B., Cheng H.-C., Mende-Mueller L., Reed J., Walsh D. A., Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. Journal of Biological Chemistry 1989 264 15 8802 8810 2-s2.0-0024353865 (Pubitemid 19151602)
18. Kleiner D. E., Stetler-Stevenson W. G., Quantitative zymography: detection of picogram quantities of gelatinases. Analytical Biochemistry 1994 218 2 325 329 2-s2.0-0028345645 10.1006/abio.1994.1186 (Pubitemid 24141631)
19. Peterson G. L., A simplification of the protein assay method of Lowry et al. Which is more generally applicable. Analytical Biochemistry 1977 83 2 346 356 2-s2.0-0017613512 (Pubitemid 8269786)
20. Poncelet A. C., Schnaper H. W., Regulation of human mesangial cell collagen expression by transforming growth factor- β 1. American Journal of Physiology. Renal Physiology 1998 275 3 F458 F466 2-s2.0-0031658170 (Pubitemid 28439864)
21. Cortes P., Zhao X., Riser B. L., Narins R. G., Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney International 1997 51 1 57 68 2-s2.0-0031059253 (Pubitemid 27064522)
22. Heilig C. W., Concepcion L. A., Riser B. L., Fraytag S. O., Zhu M., Cortes P., Hassett C. C., Gilbert J. D., Sastry K. S. S., Heilig K. O., Grondin J. M., Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. Journal of Clinical Investigation 1995 96 4 1802 1814 2-s2.0-0028863503
23. Ghosh A. K., Vaughan D. E., PAI-1 in tissue fibrosis. Journal of Cellular Physiology 2012 227 2 493 507 2-s2.0-84856302591 10.1002/jcp.22783
24. Ma L. J., Fogo A. B., PAI-1 and kidney fibrosis. Frontiers in Bioscience 2009 14 6 2028 2041 2-s2.0-63849095053 10.2741/3361
25. Hagiwara H., Kaizu K., Uriu K., Noguchi T., Takagi I., Qie Y. L., Seki T., Ariga T., Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thrombosis Research 2003 111 4-5 301 309 2-s2.0-0347063983 10.1016/j.thromres.2003.09.023 (Pubitemid 38021951)
26. Nicholas S. B., Aguiniga E., Ren Y., Kim J., Wong J., Govindarajan N., Noda M., Wang W., Kawano Y., Collins A., Hsueh W. A., Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney International 2005 67 4 1297 1307 2-s2.0-20144386753 10.1111/j.1523-1755.2005.00207.x (Pubitemid 40463106)
27. Huang Y., Border W. A., Yu L., Zhang J., Lawrence D. A., Noble N. A., A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. Journal of the American Society of Nephrology 2008 19 2 329 338 2-s2.0-39049153080 10.1681/ASN.2007040510 (Pubitemid 351240654)
28. Park J., Seo J. Y., Ha H., Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation. Korean Journal of Physiology and Pharmacology 2010 14 6 385 390 2-s2.0-79251518632 10.4196/kjpp.2010.14.6.385
29. Jönsson A., Hallengren B., Rydberg T., Melander A., Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2001 3 6 403 409 2-s2.0-0035666448 10.1046/j.1463-1326.2001.00152.x (Pubitemid 34030858)
30. Kirchheiner J., Brockmöller J., Meineke I., Bauer S., Rohde W., Meisel C., Roots I., Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clinical Pharmacology and Therapeutics 2002 71 4 286 296 2-s2.0-0036231580 10.1067/mcp.2002.122476 (Pubitemid 34311458)
31. Lee K. M., Lee H. J., Kim M. K., Kim H. S., Jung G. S., Hur S. H., Kim H. T., Cho W. H., Kim J. G., Kim B. W., Lim J. O., Choi H. S., Lee K. U., Park K. G., Lee I. K., Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. Atherosclerosis 2009 207 2 391 398 2-s2.0-70450227453 10.1016/j.atherosclerosis.2009.06.016
32. Heaton J. H., Dlakic W. M., Gelehrter T. D., Posttranscriptional regulation of PAI-I gene expression. Thrombosis and Haemostasis 2003 89 6 959 966 2-s2.0-0038150766 (Pubitemid 36798146)
33. Seino S., Shibasaki T., PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiological Reviews 2005 85 4 1303 1342 2-s2.0-25444520038 10.1152/physrev.00001.2005 (Pubitemid 41362272)
34. Thrailkill K. M., Bunn R. C., Fowlkes J. L., Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009 35 1 1 10 2-s2.0-63449086757 10.1007/s12020-008-9114-6
35. Baricos W. H., Reed J. C., Cortez S. L., Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Experimental Biology and Medicine 2003 228 9 1018 1022 2-s2.0-0141529771 (Pubitemid 37222169)
36. McLennan S. V., Martell S. K. Y., Yue D. K., Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002 51 8 2612 2618 2-s2.0-0036323281 (Pubitemid 34827414)
37. Caenazzo C., Garbisa S., Onisto M., Zampieri M., Baggio B., Gambaro G., Effect of glucose and heparin on mesangial α 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Nephrology Dialysis Transplantation 1997 12 3 443 448 2-s2.0-0031052678 10.1093/ndt/12.3.443 (Pubitemid 27105616)
38. Singh R., Song R. H., Alavi N., Pegoraro A. A., Singh A. K., Leehey D. J., High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor- β 1. Experimental Nephrology 2001 9 4 249 257 2-s2.0-0034943382 (Pubitemid 32620209)
39. Song R. H., Singh A. K., Leehey D. J., Decreased glomerular proteinase activity in the streptozotocin diabetic rat. American Journal of Nephrology 1999 19 3 441 446 2-s2.0-0033001724 10.1159/000013492 (Pubitemid 29301231)
40. Portik-Dobos V., Harris A. K., Song W., Hutchinson J., Johnson M. H., Imig J. D., Pollock D. M., Ergul A., Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. American Journal of Physiology. Regulatory Integrative and Comparative Physiology 2006 290 2 R435 R441 2-s2.0-33644871367 10.1152/ajpregu.00300.2005
41. Rodriguez W. E., Tyagi N., Joshua I. G., Passmore J. C., Fleming J. T., Falcone J. C., Tyagi S. C., Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. American Journal of Physiology. Renal Physiology 2006 291 3 F694 F701 2-s2.0-33748419495 10.1152/ajprenal.00398.2005 (Pubitemid 44343752)
42. McLennan S. V., Kelly D. J., Cox A. J., Cao Z., Lyons J. G., Yue D. K., Gilbert R. E., Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002 45 2 268 275 2-s2.0-0036189833 10.1007/s00125-001-0730-4 (Pubitemid 34208390)
43. Sun S. Z., Wang Y., Li Q., Tian Y. J., Liu M. H., Yu Y. H., Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chinese Medical Journal 2006 119 10 814 821 2-s2.0-33744474294 (Pubitemid 43796810)
44. Mankhey R. W., Wells C. C., Bhatti F., Maric C., 17 β -Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. American Journal of Physiology. Regulatory Integrative and Comparative Physiology 2007 292 2 R769 R777 2-s2.0-33846787010 10.1152/ajpregu.00375.2006 (Pubitemid 46207729)
45. Zahner G., Harendza S., Müller E., Wolf G., Thaiss F., Stahl R. A. K., Prostaglandin E2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells. Kidney International 1997 51 4 1116 1123 2-s2.0-0030609964 (Pubitemid 27186537)
46. Staun-Ram E., Goldman S., Shalev E., Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion. Reproductive Biology and Endocrinology 2009 7 article no. 135 2-s2.0-71649090820 10.1186/1477-7827-7-135
47. Katsumoto M., Shingu T., Kuwashima R., Nakata A., Nomura S., Chayama K., Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circulation Journal 2005 69 12 1547 1555 2-s2.0-28544438656 10.1253/circj.69.1547 (Pubitemid 41743974)